ExpreS2ion’s platform to be used in a novel Zika vaccine candidate

Hørsholm, Denmark, July 14, 2020 – ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that its ExpreS2 platform will be used in the production of the novel Zika-HX vaccine candidate that is being developed by Excivion Ltd., a UK-based biotechnology company. The manufacturing of the Zika-HX vaccine will be conducted together with CPI, a British independent technology innovation centre and a founding member of the UK Government’s High Value Manufacturing Catapult.

In this project, ExpreS2ion acts as a service and production platform provider, leveraging its capabilities to produce high-quality proteins for vaccines in its Drosophila S2 insect cell-based ExpreS2 protein development and production system.

ExpreS2ion’s CEO Bent Frandsen comments

“We are excited to see Excivion and CPI move forward with scaling up the manufacturing of this promising Zika vaccine using our ExpreS2 platform. For our part we are also pleased to have the opportunity to further prove the value of our technology. This once again proves that our platform is perfectly tailored for use in the development and production of vaccines with the potential to protect the world from future pandemics.”

More information can be found in the full press releases from CPI’s webpage www.uk-cpi.com/news and Excivion’s webpage www.excivion.com/news-media.About the Zika virusZika is a member of the Flavivirus genus that includes dengue, yellow fever and tick-borne encephalitis. Zika virus disease is caused by a virus transmitted primarily by Aedes mosquitoes, which bite during the day. Zika virus infection during pregnancy can cause infants to be born with microcephaly and other congenital malformations, known as congenital Zika syndrome. To date, a total of 86 countries and territories have reported evidence of mosquito-transmitted Zika infection. More information on WHO web page: https://www.who.int/news-room/fact-sheets/detail/zika-virus.

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telephone: +46 11 32 30 732

E-mail: ca@skmg.se

 

For further information about ExpreS2ion, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail:
buf@expres2ionbio.com

About ExpreS2ion

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS2ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.

About Us

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, ExpreS2, that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 250 proteins and 35 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, ExpreS2ion develops novel VLP based vaccines through the joint venture AdaptVac ApS, which was founded in 2017.

Subscribe

Media

Media